Translator Disclaimer
Presentation + Paper
19 February 2020 Perspectives on the phase 0 clinical trial of microdose administration of ABY-029 for fluorescence guided surgery: stability testing
Author Affiliations +
Abstract
ABY-029, an anti-epidermal growth factor receptor (EGFR) Affibody molecule labeled with IRDye 800CW, has been used in three Phase 0 microdosing clinical trials for fluorescence guided surgery. In May of 2019, the clinical trials were put on hold because the ABY-029 produced under Good Manufacturing Practices (GMP) for human administration had come to the end of term in which the drug product was known to be stable. Stability testing was halted due to limitations in supply of a suitable reference standard and a required test product being discontinued from commercial sale. In order to complete the remaining patients in the three clinical trials, new stability tests were developed and the GMP batch of ABY- 029 drug product tested under the new protocols. The GMP batch of ABY-029 passed all stability tests under the new protocols and the Federal Drug Administration (FDA) has given permission to complete the remaining patients with stability testing of ABY-029 performed for each patient. The tests developed and used to test ABY-029 drug product stability are described here.
Conference Presentation
© (2020) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Kimberley S. Samkoe, Sally Hull, Jonathan Elliott, Hira Shahzad Sardar, Jason Gunn, Konstantinos Linos, Laura Tafe, Brent Harris, Joachim Feldwisch, Brian W. Pogue, David Roberts, Eric Henderson, Joseph Paydarfar, and Keith Paulsen "Perspectives on the phase 0 clinical trial of microdose administration of ABY-029 for fluorescence guided surgery: stability testing", Proc. SPIE 11222, Molecular-Guided Surgery: Molecules, Devices, and Applications VI, 112220X (19 February 2020); https://doi.org/10.1117/12.2547110
PROCEEDINGS
8 PAGES + PRESENTATION

SHARE
Advertisement
Advertisement
Back to Top